Clinical Trial Update: Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brentuximab Vedotin plus antibody-drug conjugate in non-bulky limited stage Hodgkin Lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-24